Cypress Capital’s Biogen BIIB Stock Holding History

Cypress Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-158	Closed	-$55K	–	191
2021 Q2	$55K	Buy	158 +43	+37%	+$13K	0.05%	50
2021 Q1	$32K	Buy	115 +79	+219%	+$21.3K	0.01%	71
2020 Q4	$9K	Buy	+36	New	+$9.29K	﹤0.01%	72

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cypress Capital's BIIB Position: Q3 2021 in Review

Cypress Capital sold out of Biogen (BIIB) in Q3 2021, closing a stake of 158 shares — an estimated $55K sold.

Cypress Capital first reported a position in BIIB in Q4 2020 and held it in 3 quarters. The position peaked at $55K in Q2 2021. 1,039 funds tracked by Wall St. Rank hold BIIB as of Q3 2021.

Cypress Capital reported no remaining Biogen position as of Q3 2021 after selling out during the quarter.
Cypress Capital sold 158 Biogen shares in Q3 2021, an estimated $55K.
Cypress Capital first reported a position in Biogen in Q4 2020 and held it in 3 quarters.
Cypress Capital's Biogen position peaked at $55K in Q2 2021.
1,039 funds tracked by Wall St. Rank held Biogen as of Q3 2021.

Based on Cypress Capital's 13F filing for Q3 2021, filed 10 Feb 2022.